Plavix is converted to its active metabolite by CYP2C19. All PPI's are substrates for CYP2C19, but to a varying degree. Which may alter the metabolism of Plavix and reduce effectiveness. The greatest decrease with PPI's and Plavix is seen with omeprazole.
Dexlansoprazole, lansoprazole, and pantoprazole have had studies done with Plavix and will inhibit CYP2C19, however minimally (clinically insignificant) and are considered safe without dosage adjustments.
Lansoprazole is chosen out of the three due to cost.
DAW